Analysis
Can you still get compounded semaglutide or tirzepatide in 2026?
Some providers still advertise compounded GLP-1 prescriptions, but availability now depends on the actual pharmacy, prescription and post-shortage rules.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
Yes, some telehealth providers still advertise compounded semaglutide and tirzepatide prescriptions, but the shortage-era permissions are not a blanket basis for access now. Whether a particular prescription can be supplied depends on its pharmacy, applicable compounding conditions and availability in your state.
Sources checked October 9, 2026. This is an access and purchasing guide, not a determination of a seller’s compliance or your medical eligibility.
What is still being advertised?
Mochi Health’s published pricing article describes compounded semaglutide and tirzepatide, with medication prices varying by prescribed amount, state and pharmacy. OrderlyMeds also has a compounded GLP-1 offering page. Henry Meds’ program schedule lists compounded semaglutide offerings. These pages establish that the companies advertise such services; they do not prove that a specific formulation is in stock or that every applicant will receive a prescription. Mochi’s pricing article, OrderlyMeds’ offering, Henry’s program schedule
Gentle Health also advertises compounded semaglutide and tirzepatide, and DirectCare AI publishes a tirzepatide program covered in our comparison. The same limits apply: advertising a program does not establish that a particular order is available or meets every compounding condition. Our Gentle Health and DirectCare AI profiles add company and payment context.
Start with the actual product and state, rather than the generic phrase “GLP-1 program.” A provider may offer both branded and compounded medicines, or describe several pharmacy partners. Ask which product, pharmacy and service arrangement would apply to your order.
Our profiles for Mochi Health, OrderlyMeds and Henry Meds provide links and offering context. Listing a provider does not guarantee access or clear its prescriptions under every legal condition.
What changed when the shortages ended?
FDA reaffirmed the resolution of the tirzepatide injection shortage on December 19, 2024, and determined that the semaglutide injection shortage was resolved on February 21, 2025. The agency’s subsequent updates describe the end of temporary shortage-related enforcement periods. FDA’s shortage-policy timeline
Those temporary periods do not provide continuing blanket permission in 2026. FDA’s April 1, 2026 clarification states that semaglutide and tirzepatide were not on the shortage or 503B bulks lists at that time. That is a dated agency statement, not a separate live database search performed for this article.
An old page saying a drug is in shortage may therefore describe the wrong period. Look for the date of the regulatory source and the actual product it concerns. A difficulty finding a branded medicine locally is not, by itself, an FDA national shortage determination.
The end of a shortage also does not mean every type of patient-specific compounding is automatically prohibited. It changes conditions relevant to copying and bulk ingredients. The correct question is which framework applies to the prescription now, not whether compounding once occurred during a shortage.
Why the pharmacy category matters
For 503A compounding, FDA describes individual-patient prescriptions and restrictions on regularly making, or making in inordinate amounts, products essentially copying commercially available drugs. It explains a prescriber-determined, documented significant difference for an identified patient relevant to that copying definition. Other applicable conditions remain. FDA’s April 2026 clarification
For a 503B outsourcing facility, FDA describes separate bulk-ingredient eligibility through the bulks list or qualifying shortage status at compounding, distribution and dispensing. A patient-specific 503A determination does not substitute for those 503B conditions. FDA’s 503B bulk-substance resource
Ask the service which pharmacy prepares the product and which category it claims. “Our pharmacy is licensed” and “this prescription meets the applicable compounding conditions” are different claims. Neither category means the compounded drug is FDA-approved.
Does a vitamin additive guarantee continued access?
No. An added ingredient does not automatically establish a lawful exception. FDA’s April clarification specifically discusses semaglutide with B12 as a combination that may still be considered essentially a copy under its analysis. The label must not be used as a shortcut around the actual prescription and compounding conditions. FDA’s additive example
Likewise, “personalized” is an advertising description unless the relevant product and documentation are explained. Ask what the formulation contains and direct questions about its patient-specific rationale to the prescriber. This is not a process for choosing an additive yourself to secure an exception.
How to check availability in your state
Use our location guides to find covered provider offerings, then confirm with the provider that its current service and pharmacy arrangement apply to your state. Statewide online service does not imply a local office, stock at every pharmacy or availability of every product a company sells.
Ask whether the quoted offering is available for new patients, established patients or a particular transfer program. If the website describes several options, request the exact terms that would apply to you. Do not assume a discontinued program, an old customer review or another state’s offer applies today.
For a pharmacy identity check, request the preparing and dispensing names and addresses. Use FDA’s state-board directory for the appropriate official licensing records. A seller’s partner list is not a substitute for knowing which organization handles the actual prescription.
Compare the quote before committing
Once an offering is confirmed, record the medicine, consultation, membership and shipping charges, required commitment and cancellation conditions. Distinguish a monthly equivalent from the full upfront amount. A service that advertises access may still have a separate membership charge or a condition on its introductory program.
Our semaglutide and tirzepatide tables describe reviewed payment arrangements. They are not pharmacy-stock feeds, personal eligibility checks or compliance certifications. Use their source dates and conditions when asking for a current quote.
What would change the answer?
A provider may change its products, pharmacy partners or state coverage, and regulators may issue new decisions. Confirm the current offering rather than assuming that a past order guarantees the next one. A proposed regulatory action is also different from a final effective decision; the exact source and date matter.
For now, the answer is yes at the level of advertised offerings, with important conditions at the prescription level. The simplest useful check is to identify the exact product, pharmacy, state availability and payment terms, then verify any unanswered questions with the responsible service or official regulator.